Spots Global Cancer Trial Database for bone marrow disease
Every month we try and update this database with for bone marrow disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes | NCT01381809 | Myelodysplastic... | Group 2: Placeb... Group 1: Epoeti... | 18 Years - | Janssen-Cilag International NV | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) | NCT00486720 | Myelodysplastic... Blood Disease Bone Marrow Dis... | vorinostat vorinostat | 18 Years - | Merck Sharp & Dohme LLC | |
| The Effect of Music Therapy on Comfort, Pain and Anxiety | NCT05895357 | Bone Marrow Dis... Hematological M... | Musictherapy | 18 Years - 100 Years | Izmir Bakircay University | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. | NCT01844765 | Philadelphia Po... | nilotinib | 1 Year - 17 Years | Novartis | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| The Effect of Music Therapy on Comfort, Pain and Anxiety | NCT05895357 | Bone Marrow Dis... Hematological M... | Musictherapy | 18 Years - 100 Years | Izmir Bakircay University | |
| Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) | NCT00486720 | Myelodysplastic... Blood Disease Bone Marrow Dis... | vorinostat vorinostat | 18 Years - | Merck Sharp & Dohme LLC | |
| Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | NCT03514017 | Chronic Lymphoc... | Pembrolizumab Ibrutinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00471497 | Myelogenous Leu... | nilotinib imatinib | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
